Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMPOUT: IXT-m200 in Methamphetamine Use Disorder
NCT03336866Phase 2Completed
- Sponsor
- InterveXion Therapeutics
- Start
- May 2018
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of devextinetug in methamphetamine use disorder (MUD), sponsored by InterveXion Therapeutics. Started May 2018; status: completed.
02
Drugs
devextinetug
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT03336866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03336866.